A detailed history of Ausdal Financial Partners, Inc. transactions in Abbott Laboratories stock. As of the latest transaction made, Ausdal Financial Partners, Inc. holds 2,890 shares of ABT stock, worth $328,968. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,890
Previous 3,027 4.53%
Holding current value
$328,968
Previous $314,000 4.78%
% of portfolio
0.04%
Previous 0.04%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

SELL
$100.07 - $118.13 $13,709 - $16,183
-137 Reduced 4.53%
2,890 $329,000
Q2 2024

Aug 06, 2024

SELL
$100.73 - $112.44 $14,908 - $16,641
-148 Reduced 4.66%
3,027 $314,000
Q1 2024

Apr 12, 2024

SELL
$109.52 - $120.96 $9,637 - $10,644
-88 Reduced 2.7%
3,175 $360,000
Q4 2023

Jan 11, 2024

SELL
$90.19 - $110.4 $4,238 - $5,188
-47 Reduced 1.42%
3,263 $359,000
Q3 2023

Nov 08, 2023

BUY
$95.53 - $114.62 $1,146 - $1,375
12 Added 0.36%
3,310 $320,000
Q2 2023

Jul 31, 2023

SELL
$100.78 - $112.29 $30,435 - $33,911
-302 Reduced 8.39%
3,298 $359,000
Q1 2023

May 04, 2023

SELL
$96.86 - $114.01 $20,534 - $24,170
-212 Reduced 5.56%
3,600 $364,000
Q4 2022

Feb 03, 2023

SELL
$95.06 - $111.52 $33,651 - $39,478
-354 Reduced 8.5%
3,812 $418,000
Q3 2022

Nov 09, 2022

BUY
$96.76 - $112.03 $47,896 - $55,454
495 Added 13.48%
4,166 $403,000
Q2 2022

Aug 09, 2022

SELL
$102.07 - $123.37 $8,880 - $10,733
-87 Reduced 2.32%
3,671 $399,000
Q1 2022

May 04, 2022

SELL
$114.02 - $139.04 $198,280 - $241,790
-1,739 Reduced 31.64%
3,758 $445,000
Q4 2021

Feb 08, 2022

SELL
$115.53 - $141.46 $20,217 - $24,755
-175 Reduced 3.09%
5,497 $774,000
Q3 2021

Nov 01, 2021

SELL
$116.66 - $129.06 $9,332 - $10,324
-80 Reduced 1.39%
5,672 $670,000
Q2 2021

Jul 19, 2021

BUY
$105.79 - $124.53 $50,884 - $59,898
481 Added 9.13%
5,752 $667,000
Q1 2021

May 05, 2021

BUY
$108.84 - $128.23 $8,924 - $10,514
82 Added 1.58%
5,271 $632,000
Q4 2020

Feb 01, 2021

SELL
$105.0 - $114.42 $105,525 - $114,992
-1,005 Reduced 16.23%
5,189 $568,000
Q3 2020

Nov 04, 2020

BUY
$91.64 - $111.29 $129,762 - $157,586
1,416 Added 29.64%
6,194 $574,000
Q2 2020

Aug 06, 2020

SELL
$76.57 - $98.0 $63,553 - $81,340
-830 Reduced 14.8%
4,778 $437,000
Q1 2020

May 04, 2020

BUY
$62.82 - $91.86 $44,288 - $64,761
705 Added 14.38%
5,608 $550,000
Q4 2019

Feb 14, 2020

SELL
$78.51 - $87.4 $14,053 - $15,644
-179 Reduced 3.52%
4,903 $437,000
Q2 2019

Aug 05, 2019

SELL
$72.88 - $85.0 $48,246 - $56,270
-662 Reduced 11.53%
5,082 $449,000
Q1 2019

May 13, 2019

SELL
$66.22 - $80.06 $4,502 - $5,444
-68 Reduced 1.17%
5,744 $459,000
Q4 2018

Feb 11, 2019

SELL
$65.56 - $74.27 $833,660 - $944,417
-12,716 Reduced 68.63%
5,812 $420,000
Q3 2018

Nov 09, 2018

BUY
$60.81 - $73.36 $1,094 - $1,320
18 Added 0.1%
18,528 $1.36 Million
Q2 2018

Aug 08, 2018

BUY
$57.57 - $63.54 $82,728 - $91,306
1,437 Added 8.42%
18,510 $1.13 Million
Q1 2018

Apr 20, 2018

SELL
$56.27 - $63.62 $16,937 - $19,149
-301 Reduced 1.73%
17,073 $1.02 Million
Q4 2017

Feb 08, 2018

BUY
$53.68 - $57.47 $19,485 - $20,861
363 Added 2.13%
17,374 $992,000
Q3 2017

Oct 31, 2017

BUY
$48.06 - $53.64 $817,548 - $912,470
17,011
17,011 $908,000

Others Institutions Holding ABT

About ABBOTT LABORATORIES


  • Ticker ABT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 1,751,219,968
  • Market Cap $199B
  • Description
  • Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...
More about ABT
Track This Portfolio

Track Ausdal Financial Partners, Inc. Portfolio

Follow Ausdal Financial Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ausdal Financial Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ausdal Financial Partners, Inc. with notifications on news.